Welcome to our dedicated page for Adagio Medical SEC filings (Ticker: ADGM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adagio Medical Holdings, Inc. (Nasdaq: ADGM) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to official information about this medical device issuer. Adagio’s filings describe its focus on catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology for cardiac arrhythmias and provide detail on its corporate structure, governance, and capital markets activity.
Through Form 8-K current reports, Adagio furnishes information on material events such as private placement financings, preliminary clinical data releases, and key leadership appointments. For example, recent 8-K filings reference the Securities Purchase Agreement for a private placement of common stock and warrants, the closing of that financing, and press releases announcing acute results from the FULCRUM-VT pivotal IDE study and the completion of enrollment in that trial. Other 8-Ks disclose changes in executive roles, including the expansion of the Chief Business Officer’s responsibilities to include Chief Financial Officer, and the scheduling of the company’s annual meeting.
Adagio’s DEF 14A definitive proxy statement provides additional context on board elections, auditor ratification, executive compensation, security ownership, and the business combination that created Adagio Medical Holdings, Inc. It also outlines stockholder voting procedures and meeting logistics. Periodic reports such as Forms 10-Q and 10-K, when viewed alongside these current reports, give a fuller picture of Adagio’s financial condition and risk disclosures, although they are not reproduced in the text above.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key terms, clinical and regulatory milestones, and financing structures, helping readers interpret complex documents more quickly. Users can also review filings related to equity issuances and warrant terms, as well as governance documents that frame Adagio’s ongoing reporting obligations as an emerging growth company listed on The Nasdaq Stock Market LLC.
Adagio Medical Holdings, Inc. Schedule 13G: ADAR1 Capital Management, LLC and Daniel Schneeberger report beneficial ownership of 1,205,447 shares of common stock, representing 5.7% of the class based on 21,179,637 shares outstanding as of November 10, 2025. The disclosed shares consist of 1,054,697 shares held by ADAR1 Partners, LP and 150,750 shares held by Spearhead Insurance Solutions IDF, LLC as of December 31, 2025. The filing excludes milestone warrants and convertible-note issuable shares, which are subject to 4.99% beneficial ownership limitations.
Alyeska Investment Group and affiliates have disclosed a significant passive stake in Adagio Medical Holdings, Inc. As of 12/31/2025, they report beneficial ownership of 2,096,784 shares of common stock, representing 9.9% of the outstanding shares.
The position consists of 1,159,615 common PIPE shares and warrants to purchase 2,136,177 shares, but those warrants are subject to a 9.9% beneficial ownership cap. Based on 21,179,637 shares outstanding cited from a December 16, 2025 prospectus, they may currently exercise only 937,169 shares under the warrants. The filers state the holdings are in the ordinary course of business and not for changing or influencing control.
Adagio Medical Holdings, Inc. received an updated ownership report showing that Perceptive Advisors and related entities hold a majority stake in its common stock. The group, including Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd., C2 Life Sciences LLC, and Joseph Edelman, is reported to beneficially own 15,321,655 shares of common stock, representing 57.5% of the class.
This percentage is calculated based on 21,179,637 shares outstanding as of November 10, 2025 and assumes exercise of warrants for 5,445,069 shares held by the Perceptive entities. The Master Fund directly holds 9,675,684 shares plus the warrants, while C2 holds 200,902 shares. Perceptive Advisors acts as investment manager to the Master Fund and C2, and Edelman is the managing member of Perceptive Advisors, giving them shared voting and investment power over these holdings.
The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of Adagio Medical Holdings, but instead are reported as passive ownership under Schedule 13G.
Sio Capital Management, LLC reported a significant ownership position in Adagio Medical Holdings, Inc. common stock. As of December 31, 2025, Sio beneficially owned 1,288,461 shares, representing 6.08% of Adagio’s common stock, based on 21,179,637 shares outstanding as of November 10, 2025.
Sio, a Delaware limited liability company and registered investment adviser, has shared voting and dispositive power over these shares through affiliated funds. The position is certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Adagio Medical Holdings.
Adagio Medical Holdings, Inc. reported an open market share purchase by its Chief Financial Officer, Deborah Kaster. On 12/16/2025, she bought 15,000 shares of common stock at a weighted average price of $1.1982 per share, and now beneficially owns 15,000 shares directly. The transaction was carried out in multiple trades, with prices ranging from $1.11 to $1.20 per share, and was reported as a purchase under the company’s insider reporting obligations.
Adagio Medical Holdings, Inc. filed a prospectus supplement covering the potential resale of up to 67,963,695 shares of common stock by existing security holders. These shares include PIPE shares and pre-funded warrant shares, common stock issuable upon exercise of PIPE and convert warrants, and up to 46,717,980 shares issuable upon conversion of 13% senior secured convertible notes, along with various sponsor, business combination and option shares.
The supplement attaches a Current Report detailing the company’s 2025 annual stockholder meeting. Of 21,179,637 shares outstanding on the record date, 13,862,436 shares (65.45%) were represented. Stockholders elected directors Todd Usen and James L. Cox, M.D., and ratified WithumSmith+Brown, PC as independent auditor for the year ending December 31, 2025. Adagio’s common stock trades on Nasdaq under the symbol ADGM, and last traded at $1.18 per share on December 16, 2025.
Adagio Medical Holdings, Inc. has filed a prospectus supplement covering the potential resale of up to 31,818,652 shares of common stock by selling stockholders. This total includes 73,333 Registration Delay Shares already issued, up to 31,145,319 shares issuable upon conversion of 13% senior secured convertible notes at $10.00 per share, and up to 600,000 shares issuable upon exercise of warrants at $24.00 per share.
The supplement also includes the company’s latest stockholder meeting report. Shares outstanding were 21,179,637 as of the record date, with 65.45% represented at the 2025 annual meeting. Stockholders elected two directors to terms ending in 2028 and ratified WithumSmith+Brown, PC as independent auditor for the year ending December 31, 2025.
Adagio Medical Holdings, Inc. reported results from its 2025 Annual Meeting of Stockholders held on December 15, 2025. Of the 21,179,637 shares outstanding as of the record date, 13,862,436 shares, or 65.45%, were present or represented by proxy.
Stockholders elected Todd Usen and James L. Cox, M.D. as directors to serve until the 2028 annual meeting and until their successors are elected and qualified. They also approved the ratification of WithumSmith+Brown, PC as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
Adagio Medical Holdings, Inc. reported that its Chief Executive Officer and director acquired 207,315 shares of its common stock in an open market transaction on 12/12/2025.
The shares were purchased at a weighted average price of $1.09 per share, with individual trade prices ranging from $0.9258 to $1.14101. After this transaction, the reporting person directly owned 207,315 shares of Adagio Medical common stock.